Chugai Pharmaceutical has won Japan’s highest invention honor, the Imperial Invention Prize, for its groundbreaking recycling antibody technology, marking a milestone in next‑generation antibody therapeutics.
Written By: Samiskha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Chugai has been awarded The Imperial Invention Prize the highest distinction in Japan’s FY2026 National Commendation for Invention for its proprietary recycling antibody technology. The program, organized by the Japan Institute of Invention and Innovation and supported by the Imperial Household, recognizes inventions of exceptional scientific originality and industrial significance.
This is Chugai’s first Imperial Invention Prize, underscoring its leadership in antibody engineering and drug discovery innovation.
Extending Antibody Drug Activity
Chugai’s recycling antibody technology enables a single antibody molecule to repeatedly bind multiple antigens through pH‑dependent binding. By releasing antigens inside cells and re-engaging new targets, the antibodies sustain pharmacological activity and enhance antigen clearance. The approach is considered a breakthrough for therapies requiring durable efficacy, particularly in chronic disease settings.
Recognition of Long-Term Research
President and CEO Osamu Okuda said the award honors years of dedicated research by Chugai scientists and reflects the company’s commitment to advancing proprietary antibody technologies. He emphasized Chugai’s ongoing focus on refining drug discovery platforms and delivering innovative treatments for unmet medical needs worldwide.
Strengthening Next-Generation Antibody Therapeutics
Chugai has built a robust pipeline around antibody medicines and translational research. The recognition reinforces its position at the forefront of next-generation antibody therapeutics, a field driving global biopharmaceutical innovation.
References
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.
